Vertex Has Good News and Exelixis Is Reinforcing Its Outperformance

Vertex Pharmaceuticals' Product Kalydeco for CF in Young Children

Good news for Vertex (VRTX) product Kalydeco® (ivacaftor) is the first cystic fibrosis (CF) product to be prescribed for children ages six months to less than 12 months. Beneficiary children are those who have at least one mutation in their . . .

This content is for paid subscribers.
Please click here to subscribe or here to log in.